The global theranostics market is growing as healthcare facilities invest in advanced diagnostic and therapeutic solutions to improve patient outcomes. The market was valued at USD 9.18 billion in 2024 and is projected to reach USD 31.21 billion by 2035, growing at a CAGR of 11.77%.

The Theranostics Market includes oncology, neurology, cardiology, infectious diseases applications, genomics, proteomics, metabolomics, biomarkers technologies, hospitals, diagnostic laboratories, research institutes, instruments, reagents, and software products.

Hospitals hold the largest end-user share due to their comprehensive facilities and access to advanced treatment options. Their established infrastructure supports specialized care, thus enhancing patient outcomes and managing complex oncology cases effectively.

Diagnostic laboratories are emerging as the fastest-growing end-user segment, driven by increasing demand for specialized testing and biomarker analysis. This segment benefits from advanced laboratory capabilities, specialized expertise, and growing adoption of precision diagnostic approaches.

Research institutes, pharmaceutical companies, and academic institutions also contribute substantially to the market, though they occupy smaller portions of the overall landscape. Growth trends indicate a robust demand for theranostic solutions supporting diverse scientific and clinical needs across various healthcare settings.

Bristol-Myers Squibb continues expanding oncology portfolios through targeted immunotherapy research and clinical development initiatives. The company's investments in theranostic programs are strengthening its position in the cancer immunotherapy market.

Merck KGaA maintains strong diagnostics and therapeutic capabilities through integrated healthcare solutions. The company's focus on innovation and strategic partnerships supports increasing clinical demand for precise diagnostic and therapeutic applications.

The future market will depend on rising cancer incidence, supportive regulatory frameworks, growing demand for personalized medicine, increasing investment in healthcare infrastructure, and technological advancements in theranostics.

FAQs

Q1. Why do hospitals dominate the theranostics market end-user segment?
Hospitals dominate due to their comprehensive facilities, advanced treatment options, and specialized cancer care capabilities.

Q2. What is driving the growth of diagnostic laboratories?
Increasing demand for specialized testing, biomarker analysis, and advanced laboratory capabilities are driving diagnostic laboratory adoption.

Tags: theranostics market, hospitals, diagnostic laboratories, research institutes, end users